López Cano, José JavierGonzález-Cela Casamayor, Miriam AnaAndrés Guerrero, VanesaVicario De La Torre, MartaBenítez Del Castillo Sánchez, José ManuelHerrero Vanrell, María Del RocíoMolina Martínez, Irene Teresa2024-11-142024-11-142023J.J. López-Cano, M.A. González-Cela-Casamayor, V. Andrés-Guerrero, M. Vicario -de-la-Torre, J.M. Benítez-del-Castillo, R. Herrero-Vanrell, I.T. Molina-Martínez, New trends towards glaucoma treatment: Topical osmoprotective microemulsions loaded with latanoprost, The Ocular Surface, Volume 29, 2023, Pages 314-330, https://doi.org/10.1016/j.jtos.2023.05.013.1542-012410.1016/j.jtos.2023.05.013https://hdl.handle.net/20.500.14352/1106022023 Acuerdos transformativos CRUEThe chronic use of hypotensive agents eventually leads to ocular surface damage and poor patient compliance during glaucoma management. Thus, new sustained drug delivery systems are needed. This work aimed to develop osmoprotective latanoprost-loaded microemulsion formulations as new potential glaucoma treatments with ocular surface protective properties. The microemulsions were characterized and latanoprost encapsulation efficacy determined. In-vitro tolerance, osmoprotective efficacy, cell internalization as well as cell-microemulsion interactions and distribution were performed. In vivo hypotensive activity was conducted in rabbits to assess intraocular pressure reduction and relative ocular bioavailability. Physicochemical characterization showed nanodroplet sizes within 20–30 nm, being in vitro tolerance within 80 and 100% viability in corneal and conjunctival cells. Besides, microemulsions exhibited higher protection under hypertonic conditions than untreated cells. Cell fluorescence lasted for 11 days after short exposure to coumarin-loaded microemulsions (5 min) showing extensive internalization in different cell compartments by electronic microscopy. In vivo studies exhibited that a single instillation of latanoprost-loaded microemulsions reduced the intraocular pressure for several days (4–6 days without polymer and 9–13 days with polymers). Relative ocular bioavailability was 4.5 and 19 times higher than the marketed formulation. These findings suggest the use of these microemulsions as potential combined strategies for extended surface protection and glaucoma treatment.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/journal articlehttps://doi.org/10.1016/j.jtos.2023.05.013open access663/665615.01/.03OsmoprotectionMicroemulsionLatanoprostOsmoprotective microemulsionGlaucomaCell internalizationFarmacología (Farmacia)Tecnología de los alimentos3209 Farmacología